It is evident that GLP-1RAs, as incretins that promote postprandial insulinsecretion, exhibit glucose-lowering mechanisms that include increasing endogenousinsulin secretion, reducing gluconeogenesis, inhibiting glucagon production bypancreatic α-cells, and decreasing β-cell apoptosis.Furthermore, they have been found to delay gastric emptying, promote weight loss,increase satiety, reduce blood pressure, improve dyslipidemia, alleviateinflammation, improve albuminuria, enhance cardiovascular function, and preventthrombosis formation [26, 27]. The gene discussed is GCG; the disease is metabolic syndrome.